Deep Value: cash covers more than 100% of the stock price

This company holds roughly $28,506 in cash and investments — more than its entire stock-market value, based on its latest quarterly filing. You're paying very little for the actual business. Sometimes that's a genuine bargain or a takeover target, sometimes it's cheap for a reason. Not a buy signal on its own — always ask why it's this cheap.

Pressure BioSciences

PBIO

Medical - Specialties · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$16,387

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+1074.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.0M (2019) → 23.3M (2023)

Winston Score History

The full picture

Pressure BioSciences is a small biotechnology tools company that uses high-pressure technology to help scientists prepare biological samples for research. Its main product line is called PCT (Pressure Cycling Technology), which uses cycles of high and low pressure to break open cells and extract proteins, DNA, and other molecules. Its customers are mostly research laboratories, universities, pharmaceutical companies, and government agencies.

The company sells instruments, consumables, and reagents, and also earns some revenue from grants and collaborations. It operates primarily in the United States but sells to research institutions globally. Despite a 40% gross margin on its products, the company spends far more than it earns, resulting in a deeply negative operating margin, which signals it is not yet profitable. The biggest risk facing Pressure BioSciences is its ongoing need for external financing to fund operations, as it has a history of losses and a very small revenue base that makes long-term sustainability uncertain.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-17.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+73.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$1M/ year

↑ Rising (+41% vs prior year)

69.1% of revenue

3.8x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

0.7%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$78,028 cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Pressure BioSciences is putting 69% of revenue into R&D and that number is rising. That's 3.8x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

10.5%

Thin — 10.5% gross margin

Profit after running costs

Operating Margin

-457.2%

Losing money on operations — -457.2%

Return on the money invested

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-25.3%

Shrinking sales (-25.3% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-796.7%

Burning cash (-796.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial